Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
暂无分享,去创建一个
Elaine Coustan-Smith | Dario Campana | Xueyuan Cao | Ching-Hon Pui | Stanley B Pounds | J. Downing | S. Shurtleff | S. Raimondi | D. Campana | C. Pui | R. Ribeiro | E. Coustan-Smith | J. Taub | J. Rubnitz | S. Pounds | W. Bowman | M. Onciu | Xueyuan Cao | W. Bowman | G. Dahl | James R Downing | Susana C Raimondi | Hiroto Inaba | Raul C Ribeiro | Jeffrey E Rubnitz | H. Inaba | B. Degar | W. Leung | J. Jacobsen | Sheila A Shurtleff | W Paul Bowman | Mihaela Onciu | Wing Leung | Jeffrey W Taub | Gary V Dahl | Barbara Degar | Kathleen Y Wang | Jeffrey Jacobsen | Kathleen Y. Wang | S. Shurtleff | Stanley B. Pounds | Kathleen Y. Wang | Raul C. Ribeiro | Gary V. Dahl | W. Paul Bowman | Jeffrey W. Taub | James R. Downing | W. Bowman
[1] M. Caligiuri,et al. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay , 1998, Leukemia.
[2] T. Haferlach,et al. Monitoring of minimal residual disease in acute myeloid leukemia. , 2005, Critical reviews in oncology/hematology.
[3] Ursula Creutzig,et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Breuning,et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion , 2002, British journal of haematology.
[5] High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome , 1997 .
[6] D. Campana,et al. Minimal residual disease quantitation in acute myeloid leukemia. , 2009, Clinical lymphoma & myeloma.
[7] S. Shurtleff,et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. , 1995, Blood.
[8] L. Shih,et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. , 2002, Blood.
[9] S. Langabeer,et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. , 2002, Blood.
[10] P. Marlton,et al. A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse , 2008, Leukemia & lymphoma.
[11] G. Morgan,et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. , 2000, Blood.
[12] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[13] M. Caligiuri,et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. , 2001, Leukemia.
[14] J. Downing,et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. , 1993, Blood.
[15] F. Behm,et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.
[16] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[17] V. V. D. van der Velden,et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Hills,et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Downing,et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[21] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[22] R. Gray,et al. A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.
[23] D. Campana,et al. Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. , 2009 .
[24] C. Flamant,et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Cilloni,et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts , 2002, Leukemia.
[26] D. Reinhardt,et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Elaine Coustan-Smith,et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.
[28] S. Fröhling,et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Villamor,et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.
[30] P. Vyas,et al. Assessment of minimal residual disease in acute myeloid leukemia , 2010, Current opinion in oncology.
[31] W. Hiddemann,et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.
[32] J. Dongen,et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.
[33] S. Raimondi,et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia , 2012, Cancer.
[34] W. Hiddemann,et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. , 2004, Blood.
[35] R. Hanada,et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Z. Estrov,et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Radich,et al. Structural and numerical variation of FLT3/ITD in pediatric AML. , 2008, Blood.
[38] M. Baccarani,et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. , 2002, Blood.
[39] J. Downing,et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia , 2003, British journal of haematology.
[40] D. H. Mellor,et al. Real time , 1981 .
[41] Monitoring of minimal residual disease in acute myeloid leukemia , 2008, Cancer.
[42] F. Lo Coco,et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Teigler‐Schlegel,et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement , 2003, Leukemia.
[44] A. Órfão,et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. , 2001, Blood.
[45] R. Arceci,et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.
[46] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] S. Fröhling,et al. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. , 2005, Haematologica.
[48] C. Preudhomme,et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) , 2005, Leukemia.
[49] Augustin Ferrant,et al. Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.
[50] D. Cilloni,et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. , 2003, Blood.
[51] R. Pieters,et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.
[52] Torsten Haferlach,et al. The role of multiparameter flow cytometry for disease monitoring in AML. , 2010, Best practice & research. Clinical haematology.
[53] M. Caligiuri,et al. Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia , 2001, Leukemia.